Pozen MT 100 review

FDA's Peripheral & Central Nervous System Drugs Advisory Committee will meet Aug. 4 to discuss tardive dyskinesia risks with Pozen's MT 100 (metoclopromide/naproxen) for treatment of migraine. A tentative meeting on the issue set for May was postponed by FDA due to what Pozen said were scheduling conflicts (1"The Pink Sheet" May 2, 2005, In Brief). The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m. [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...